Dr. Flood earned her undergraduate degree from Harvard University in 1995 and her doctorate from Tufts University in 1999. She is board certified in pediatrics as well as pediatric hematology/oncology. She has been serving as an Assistant Professor…
Dr. Smith's research focuses on better understanding the development of factor VIII inhibitors. Specifically, she will focus on the effects of chemical signals, or cytokines, secreted by helper T cells on the development of inhibitor antibodies. She…
Established in 1948, the National Bleeding Disorders Foundation has long been one of the nation’s leading organizations dedicated to serving patients and families living with inheritable blood and bleeding disorders such as hemophilia, von…
NHF celebrates its 75th anniversary in 2023! To honor this momentous occasion, the organization is launching a celebratory and reflective campaign entitled “The Red Thread” which will tell the story of the organization’s history and evolution…
FOR IMMEDIATE RELEASE
December 13, 2022
MEDIA CONTACT:
Ilana Ostrin
212-328-3769
iostrin@hemophilia.org
Organization set to look back while moving ahead during historic year
NEW YORK — In 2023…
Spark has announced updated multi-year results from its phase 1/2 clinical trial of SPK-8011, the company’s investigational gene therapy for hemophilia A. The results were presented at the recently concluded 64th American Society of Hematology…
inSourceRX Prescription Savings
Speaker(s): Jim Christensen & Maureen Parsons
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…
Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
Speaker(s): Sylvia Fong
NHF's Wednesday Webinars are a free education series…